XORTX Therapeutics Files September 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, 6-K, foreign-private-issuer
TL;DR
XORTX filed its monthly 6-K, confirming 20-F annual reports and CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on September 3, 2025, to report its activities for the month of September 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing serves as an update for investors on the company's regulatory status and reporting schedule, confirming its adherence to SEC requirements for foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine administrative filing (6-K) confirming reporting status and not disclosing new material financial or operational information.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- September 3, 2025 (date) — Filing Date
- Allen Davidoff (person) — Chief Executive Officer
- Form 20-F (document) — Annual Report Filing
- Form 6-K (document) — Report Type
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of September 2025.
Which annual report form will XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed this report on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the report on behalf of XORTX Therapeutics Inc.
What is the filing date of this report?
The filing date of this report is September 3, 2025.
What is the company's primary business classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-09-03 11:35:08
Filing Documents
- f6k_090325.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 12KB
- 0001171843-25-005700.txt ( ) — 17KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: September 3, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated September 3, 2025